Terns Pharmaceuticals Stock Forecast, Price & News

Terns Pharmaceuticals (NASDAQ:TERN) Frequently Asked Questions

Is Terns Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Terns Pharmaceuticals stock.
View analyst ratings for Terns Pharmaceuticals or view top-rated stocks.

When is Terns Pharmaceuticals' next earnings date?

Terns Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Terns Pharmaceuticals.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its earnings results on Monday, November, 15th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.64) by $0.17.
View Terns Pharmaceuticals' earnings history.

What price target have analysts set for TERN?

3 brokerages have issued 1-year target prices for Terns Pharmaceuticals' shares. Their forecasts range from $21.00 to $32.00. On average, they expect Terns Pharmaceuticals' share price to reach $26.50 in the next year. This suggests a possible upside of 373.2% from the stock's current price.
View analysts' price targets for Terns Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Terns Pharmaceuticals' key executives?

Terns Pharmaceuticals' management team includes the following people:

• Mr. Senthil Vel Sundaram, CEO & Director (Age 43, Pay $581.77k)
• Dr. Erin Quirk M.D., Head of R&D, Pres & Chief Medical Officer (Age 50, Pay $549.39k)
• Dr. Weidong Zhong Ph.D., Co-Founder, Director & Chief Scientific Officer (Age 55)
• Dr. Mark Joseph Vignola, CFO & Treasurer (Age 43, Pay $402.15k)
• Mr. Seokho Yoon Esq., COO, Gen. Counsel & Sec. (Age 43)

Who are some of Terns Pharmaceuticals' key competitors?

Some companies that are related to Terns Pharmaceuticals include Kronos Bio (KRON), Pharming Group (PHAR), Chinook Therapeutics (KDNY), Celularity (CELU), Foghorn Therapeutics (FHTX), Atea Pharmaceuticals (AVIR), Mirum Pharmaceuticals (MIRM), Kinnate Biopharma (KNTE), POINT Biopharma Global (PNT), Calliditas Therapeutics AB (publ) (CALT), Phathom Pharmaceuticals (PHAT), Pharvaris (PHVS), Fulcrum Therapeutics (FULC), Albireo Pharma (ALBO) and Relmada Therapeutics (RLMD).
View all of TERN's competitors.

When did Terns Pharmaceuticals IPO?

(TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

What is Terns Pharmaceuticals' stock symbol?

Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN."

Who are Terns Pharmaceuticals' major shareholders?

Terns Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Marquette Asset Management LLC (0.07%). Company insiders that own Terns Pharmaceuticals stock include James E Flynn and Vivo Capital Fund Viii, LP.
View institutional ownership trends for Terns Pharmaceuticals.

Which major investors are buying Terns Pharmaceuticals stock?

TERN stock was bought by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Terns Pharmaceuticals stock in the last two years include James E Flynn, and Vivo Capital Fund Viii, LP.
View insider buying and selling activity for Terns Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terns Pharmaceuticals' stock price today?

One share of TERN stock can currently be purchased for approximately $5.60.

How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals has a market capitalization of $141.50 million. The company earns $-40.05 million in net income (profit) each year or ($5.43) on an earnings per share basis.

How many employees does Terns Pharmaceuticals have?

Terns Pharmaceuticals employs 30 workers across the globe.

What is Terns Pharmaceuticals' official website?

The official website for Terns Pharmaceuticals is www.ternspharma.com.

Where are Terns Pharmaceuticals' headquarters?

Terns Pharmaceuticals is headquartered at 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404.

How can I contact Terns Pharmaceuticals?

Terns Pharmaceuticals' mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The company can be reached via email at [email protected].